MktsMarkets

Enanta Pharmaceuticals, Inc.
NASDAQ: ENTAKey statistics
ENTA News
Stories mentioning ENTA from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 17,159 | 18,615 | 15,125 | 18,314 | 14,926 | 16,959 | 14,607 | 17,971 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 19,443 | 20,859 | 23,809 | 27,210 | 28,065 | 27,656 | 30,778 | 28,742 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (11,852) | (11,253) | (18,386) | (18,893) | (24,527) | (23,543) | (29,854) | (24,185) |
| Interest Income | ||||||||
| Interest Expense | 2,355 | |||||||
| Other Expense | ||||||||
| Pretax Income | (13,084) | (11,914) | (18,668) | (18,226) | (23,949) | (22,706) | (29,186) | (23,053) |
| Tax Provision | 7.00 | 24.00 | 32.00 | 29.00 | (1,305) | (416.00) | (363.00) | (395.00) |
| Net Income (Loss) | (13,091) | (11,938) | (18,700) | (18,255) | (22,644) | (22,290) | (28,823) | (22,658) |
| Earnings Per Share (Basic) | (0.45) | (0.42) | (890.48) | (0.85) | (1.06) | (1.05) | (1,373) | (1.07) |
| Earnings Per Share (Diluted) | (0.45) | (0.42) | (890.48) | (0.85) | (1.06) | (1.05) | (1,373) | (1.07) |
| Weighted Average Shares Outstanding (Basic) | 29,040 | 28,748 | 21.00 | 21,377 | 21,355 | 21,238 | 21.00 | 21,180 |
| Weighted Average Shares Outstanding (Diluted) | 29,040 | 28,748 | 21.00 | 21,377 | 21,355 | 21,238 | 21.00 | 21,180 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ENTA
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is a stock listed on the Nasdaq Stock Market under the ticker symbol ENTA. It last traded at $7.98 (Nov 19, 2026, 4:00 PM ET), down 3.0% on the day. That gives Enanta Pharmaceuticals a market capitalisation of $239.7M.
Over the past 52 weeks ENTA has traded between $8.61 and $17.15.
Revenue for the quarter ended Mar 31, 2026 was $17.2M; a net loss of $13.1M. Revenue was up 15.0% from $14.9M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $17.2M | -$13.1M | -76.3% |
| Dec 31, 2025 | $18.6M | -$11.9M | -64.1% |
| Sep 30, 2025 | $15.1M | -$18.7M | -123.6% |
| Jun 30, 2025 | $18.3M | -$18.3M | -99.7% |
From Enanta Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…